MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogeneti...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2006-07-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC1502153?pdf=render |
_version_ | 1819158740168867840 |
---|---|
author | Yana Pikman Benjamin H Lee Thomas Mercher Elizabeth McDowell Benjamin L Ebert Maricel Gozo Adam Cuker Gerlinde Wernig Sandra Moore Ilene Galinsky Daniel J DeAngelo Jennifer J Clark Stephanie J Lee Todd R Golub Martha Wadleigh D Gary Gilliland Ross L Levine |
author_facet | Yana Pikman Benjamin H Lee Thomas Mercher Elizabeth McDowell Benjamin L Ebert Maricel Gozo Adam Cuker Gerlinde Wernig Sandra Moore Ilene Galinsky Daniel J DeAngelo Jennifer J Clark Stephanie J Lee Todd R Golub Martha Wadleigh D Gary Gilliland Ross L Levine |
author_sort | Yana Pikman |
collection | DOAJ |
description | The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event in these patients, and that enzymatic inhibition of JAK2V617F may be of therapeutic benefit in this context. However, a significant proportion of patients with ET or MF are JAK2V617F-negative. We hypothesized that activation of the JAK-STAT pathway might also occur as a consequence of activating mutations in certain hematopoietic-specific cytokine receptors, including the erythropoietin receptor (EPOR), the thrombopoietin receptor (MPL), or the granulocyte-colony stimulating factor receptor (GCSFR).DNA sequence analysis of the exons encoding the transmembrane and juxtamembrane domains of EPOR, MPL, and GCSFR, and comparison with germline DNA derived from buccal swabs, identified a somatic activating mutation in the transmembrane domain of MPL (W515L) in 9% (4/45) of JAKV617F-negative MF. Expression of MPLW515L in 32D, UT7, or Ba/F3 cells conferred cytokine-independent growth and thrombopoietin hypersensitivity, and resulted in constitutive phosphorylation of JAK2, STAT3, STAT5, AKT, and ERK. Furthermore, a small molecule JAK kinase inhibitor inhibited MPLW515L-mediated proliferation and JAK-STAT signaling in vitro. In a murine bone marrow transplant assay, expression of MPLW515L, but not wild-type MPL, resulted in a fully penetrant myeloproliferative disorder characterized by marked thrombocytosis (Plt count 1.9-4.0 x 10(12)/L), marked splenomegaly due to extramedullary hematopoiesis, and increased reticulin fibrosis.Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF. The bone marrow transplant model of MPLW515L-mediated myeloproliferative disorders (MPD) exhibits certain features of human MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation. Further analysis of positive and negative regulators of the JAK-STAT pathway is warranted in JAK2V617F-negative MPD. |
first_indexed | 2024-12-22T16:29:27Z |
format | Article |
id | doaj.art-41e9292b1f724c7da3d9525fa803db03 |
institution | Directory Open Access Journal |
issn | 1549-1277 1549-1676 |
language | English |
last_indexed | 2024-12-22T16:29:27Z |
publishDate | 2006-07-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS Medicine |
spelling | doaj.art-41e9292b1f724c7da3d9525fa803db032022-12-21T18:20:05ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762006-07-0137e27010.1371/journal.pmed.0030270MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.Yana PikmanBenjamin H LeeThomas MercherElizabeth McDowellBenjamin L EbertMaricel GozoAdam CukerGerlinde WernigSandra MooreIlene GalinskyDaniel J DeAngeloJennifer J ClarkStephanie J LeeTodd R GolubMartha WadleighD Gary GillilandRoss L LevineThe JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event in these patients, and that enzymatic inhibition of JAK2V617F may be of therapeutic benefit in this context. However, a significant proportion of patients with ET or MF are JAK2V617F-negative. We hypothesized that activation of the JAK-STAT pathway might also occur as a consequence of activating mutations in certain hematopoietic-specific cytokine receptors, including the erythropoietin receptor (EPOR), the thrombopoietin receptor (MPL), or the granulocyte-colony stimulating factor receptor (GCSFR).DNA sequence analysis of the exons encoding the transmembrane and juxtamembrane domains of EPOR, MPL, and GCSFR, and comparison with germline DNA derived from buccal swabs, identified a somatic activating mutation in the transmembrane domain of MPL (W515L) in 9% (4/45) of JAKV617F-negative MF. Expression of MPLW515L in 32D, UT7, or Ba/F3 cells conferred cytokine-independent growth and thrombopoietin hypersensitivity, and resulted in constitutive phosphorylation of JAK2, STAT3, STAT5, AKT, and ERK. Furthermore, a small molecule JAK kinase inhibitor inhibited MPLW515L-mediated proliferation and JAK-STAT signaling in vitro. In a murine bone marrow transplant assay, expression of MPLW515L, but not wild-type MPL, resulted in a fully penetrant myeloproliferative disorder characterized by marked thrombocytosis (Plt count 1.9-4.0 x 10(12)/L), marked splenomegaly due to extramedullary hematopoiesis, and increased reticulin fibrosis.Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF. The bone marrow transplant model of MPLW515L-mediated myeloproliferative disorders (MPD) exhibits certain features of human MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation. Further analysis of positive and negative regulators of the JAK-STAT pathway is warranted in JAK2V617F-negative MPD.http://europepmc.org/articles/PMC1502153?pdf=render |
spellingShingle | Yana Pikman Benjamin H Lee Thomas Mercher Elizabeth McDowell Benjamin L Ebert Maricel Gozo Adam Cuker Gerlinde Wernig Sandra Moore Ilene Galinsky Daniel J DeAngelo Jennifer J Clark Stephanie J Lee Todd R Golub Martha Wadleigh D Gary Gilliland Ross L Levine MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine |
title | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
title_full | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
title_fullStr | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
title_full_unstemmed | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
title_short | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
title_sort | mplw515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia |
url | http://europepmc.org/articles/PMC1502153?pdf=render |
work_keys_str_mv | AT yanapikman mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT benjaminhlee mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT thomasmercher mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT elizabethmcdowell mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT benjaminlebert mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT maricelgozo mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT adamcuker mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT gerlindewernig mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT sandramoore mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT ilenegalinsky mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT danieljdeangelo mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT jenniferjclark mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT stephaniejlee mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT toddrgolub mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT marthawadleigh mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT dgarygilliland mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia AT rossllevine mplw515lisanovelsomaticactivatingmutationinmyelofibrosiswithmyeloidmetaplasia |